drugset / Trial / NCT02159066
LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The primary purpose of this study is to assess the anti-tumor activity of LGX818/MEK162 in combination with targeted agents after progression on LGX818/MEK162 combination therapy, as well as the safety and tolerability of the novel triple combinations.
Timeline
- Start
- 2014-07-23
- Primary completion
- 2023-01-10
- Completion
- 2023-01-10
Publications
- Dummer R, Sandhu S, Miller WH Jr, Butler MO, Taylor MH, Heinzerling L, Blank CU, Couselo EM, Burris HA 3rd, Postow MA, Chmielowski B, Middleton MR, Berking C, Hassel JC, Gesierich AH, Mauch C, Kleha JF, Polli A, Harney AS, di Pietro A, Ascierto PA. Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma. Future Oncol. 2026 Apr;22(9):995-1013. doi: 10.1080/14796694.2026.2643481. Epub 2026 Mar 31.
- Nassar KW, Hintzsche JD, Bagby SM, Espinoza V, Langouet-Astrie C, Amato CM, Chimed TS, Fujita M, Robinson W, Tan AC, Schweppe RE. Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor-Resistant Melanoma. Mol Cancer Ther. 2021 Oct;20(10):2049-2060. doi: 10.1158/1535-7163.MCT-20-1126. Epub 2021 Aug 10.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Binimetinib | Small molecule | — | — |
| Subject | Buparlisib | Small molecule | — | — |
| Subject | Capmatinib | Small molecule | — | — |
| Subject | Encorafenib | Small molecule | — | — |
| Subject | Infigratinib | Small molecule | — | — |
| Subject | Ribociclib | Small molecule | — | — |